Skip to main content

VB

ETF

VB

ETF
Various
Various

Performance overview

VB Price
Price Chart

Forward-looking statistics

Beta
0.91
Risk
17.56%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

An ETF that tracks the performance of small-cap U.S. companies.

Fund info

An ETF that tracks the performance of small-cap U.S. companies.

Investing methodPassively Managed
DiversifiedYes
Expense ratio0.05%
Asset classEquities

Top holdings

Axon Enterprise Inc0.47%
Smurfit WestRock PLC0.42%
Deckers Outdoor Corp0.40%
Builders FirstSource Inc0.37%
Atmos Energy Corp0.35%
Booz Allen Hamilton Holding Corp Class A0.34%
Carlisle Companies Inc0.34%
PTC Inc0.34%
EMCOR Group Inc0.33%
Other96.64%

Sector exposure

Industrials19.70%
Financials14.50%
Consumer Discretionary13.20%
Information Technology12.10%
Health Care10.70%
Materials5.20%
Energy4.00%
Consumer Staples3.80%
Utilities3.00%
Other13.80%

Country exposure

United States100.00%
Other0.00%

Company info

SectorVarious
IndustryVarious
Website—
AUM$57.8B

Security info

ExchangeNyse American
Type of shareN/A
Earnings per share (EPS)—
Dividend per share$3.68
Revenue per share—
Avg trading volume (30 day)$184M
Avg trading volume (10 day)$194M
Put-call ratioN/A

Macro factor sensitivity

Growth+0.9
Credit+4.1
Liquidity-0.1
Inflation-2.0
Commodities-0.1
Interest Rates-1.5

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend dayMarch 27, 2025

News

How Are Residential REITs Positioned in Q2 as Demand Stays Resilient?

Apartment demand surges in Q2, boosting occupancy and stability for residential REITs like AVB, EQR, ESS and UDR.

Zacks Investment Research (July 11, 2025)
Should Vanguard Small-Cap ETF (VB) Be on Your Investing Radar?

If you're interested in broad exposure to the Small Cap Blend segment of the US equity market, look no further than the Vanguard Small-Cap ETF (VB), a passively managed exchange traded fund launched on 01/26/2004.

Zacks Investment Research (July 10, 2025)
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy

Nuvation Bio (NUVB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (July 9, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free